Intangible Assets, Net - Additional Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			$ 170,000
Weighted-average useful life of intangible assets	7 years 8 months 12 days
Amortization expense of intangible assets	$ 500,000	$ 500,000
CDE In- Process Research and Development
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments	$ 0
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period	6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period	12 years
Hanmi Pharmaceuticals Co. Ltd. | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 400,000
Acquired finite-lived intangible assets, amortization period	12 years 9 months
Gland Pharma Limited | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 4,400,000
Acquired finite-lived intangible assets, amortization period	5 years
MAIA Pharmaceuticals, Inc | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 4,000,000
Acquired finite-lived intangible assets, amortization period	7 years
MAIA Pharmaceuticals, Inc | Licenses of Other Specialty Products
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 700,000